Colchicine

First marketed in 1921

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H25NO6
Molecular Weight	399.437
Optical Activity	( - )
Additional Stereochemistry	Yes
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0
Stereo Comments	M-helix

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC2=C(C(OC)=C1OC)C3=CC=C(OC)C(=O)C=C3[C@H](CC2)NC(C)=O

InChI

InChIKey=IAKHMKGGTNLKSZ-INIZCTEOSA-N

InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C22H25NO6
Molecular Weight	399.437
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugs.com/pro/colchicine.html

Colchicine is an alkaloid obtained from the plant colchicum autumnale (also known as "meadow saffron"). Colchicine is an alternative medication for those unable to tolerate NSAIDs in gout. Mechanism of action of colchicine is inhibition of microtubule polymerization by binding to tubulin. Availability of tubulin is essential to mitosis, so colchicine effectively unctions as a "mitotic poison" or spindle poison.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tubulin 69 Target ID: CHEMBL2095182 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26132075	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gout 28 Sources: https://www.drugs.com/pro/colchicine.html	Preventing		Approved 8429	COLCRYS Approved Use Colchicine capsules are indicated for prophylaxis of gout flares in adults. Colchicine disrupts the polymerization of β-tubulin into microtubules, thereby preventing the activation, degranulation, and migration of neutrophils to sites of inflammation. Launch Date 2009
Familial mediterranean fever 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022351lbl.pdf	Primary		Approved 8429	COLCRYS Approved Use Colchicine is indicated for Familial Mediterranean fever (FMF) in adults and children 4 years or older Launch Date 2009

C_max

Value	Dose	Analyte	Population
1.68 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf	0.6 mg single, oral dose: 0.6 mg route of administration: Oral experiment type: SINGLE co-administered:	COLCHICINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
2.16 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf	0.6 mg single, oral dose: 0.6 mg route of administration: Oral experiment type: SINGLE co-administered:	COLCHICINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
2023.29 pg/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00960323	0.6 mg single, oral dose: 0.6 mg route of administration: oral experiment type: single co-administered:	COLCHICINE plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
18.47 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf	0.6 mg single, oral dose: 0.6 mg route of administration: Oral experiment type: SINGLE co-administered:	COLCHICINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
19.9 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf	0.6 mg single, oral dose: 0.6 mg route of administration: Oral experiment type: SINGLE co-administered:	COLCHICINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
8717.33 pg*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00960323	0.6 mg single, oral dose: 0.6 mg route of administration: oral experiment type: single co-administered:	COLCHICINE plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
30.54 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf	0.6 mg single, oral dose: 0.6 mg route of administration: Oral experiment type: SINGLE co-administered:		COLCHICINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
31.04 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf	0.6 mg single, oral dose: 0.6 mg route of administration: Oral experiment type: SINGLE co-administered:		COLCHICINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
61% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf			COLCHICINE serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
50 mg single, oral Overdose Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/33128536	unknown, 42 years n = 1 Health Status: unknown Age Group: 42 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33128536	Other AEs: Myelosuppression... Other AEs: Myelosuppression (grade 4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/33128536
3 mg 1 times / day multiple, oral MTD Dose: 3 mg, 1 times / day Route: oral Route: multiple Dose: 3 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30604205/	unhealthy, 44 years (range: 39.5–48.5 years) n = 15 Health Status: unhealthy Condition: familial Mediterranean fever Age Group: 44 years (range: 39.5–48.5 years) Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/30604205/	Sources: https://pubmed.ncbi.nlm.nih.gov/30604205/
1 mg 1 times / week multiple, intravenous Dose: 1 mg, 1 times / week Route: intravenous Route: multiple Dose: 1 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/30604205	unhealthy, 44 years (range: 39.5–48.5 years) n = 15 Health Status: unhealthy Condition: familial Mediterranean fever Age Group: 44 years (range: 39.5–48.5 years) Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/30604205	Other AEs: Nausea, Vomiting... Other AEs: Nausea (27%) Vomiting (13%) Diarrhea (20%) Injection site reactions (20%) Myalgia (27%) Arthralgia (7%) Allergic reaction (7%) Sources: https://pubmed.ncbi.nlm.nih.gov/30604205
12 mg single, oral Overdose Dose: 12 mg Route: oral Route: single Dose: 12 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31348292	unknown, 56 years n = 1 Health Status: unknown Age Group: 56 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/31348292	Other AEs: Rhabdomyolysis... Other AEs: Rhabdomyolysis (grade 5, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/31348292
1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17692130	unhealthy, 79 years n = 1 Health Status: unhealthy Age Group: 79 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/17692130	Disc. AE: Acute pancreatitis, Epigastric pain... AEs leading to discontinuation/dose reduction: Acute pancreatitis (1 patient) Epigastric pain (severe, 1 patient) Nausea (1 patient) Vomiting (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17692130
0.6 mg 2 times / day multiple, oral Dose: 0.6 mg, 2 times / day Route: oral Route: multiple Dose: 0.6 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01985425	unhealthy n = 49 Health Status: unhealthy Condition: Thoracic Surgery Population Size: 49 Sources: https://clinicaltrials.gov/ct2/show/NCT01985425	Other AEs: Acute respiratory distress syndrome, Fall... Other AEs: Acute respiratory distress syndrome (serious, 3 patients) Fall (serious, 2 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01985425

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	substrate 1037	substrate 1217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2A6 543 CYP2C19 991 CYP2E1 667 P-gp 1537

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2A6 543	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/8960070/	no
CYP2C19 991	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/8960070/	no
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/8960070/	no
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/8960070/	no
CYP2E1 667	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/8960070/	no
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf#page=2; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204820Orig1s000ClinPharmR.pdf#page=11 Page: 2.0	yes	likely (co-administration study) Comment: Although there are no published case reports for colchicine toxicity when co-administered with the 4 inhibitors that the sponsor employed, i.e., voriconazole, fluconazole, cimetidine and propafenone, several published case reports indicate that colchicine toxicity is observed when it is co-administered with drugs that are potent inhibitors of both P-gp and CYP3A4 (e.g., clarithromycin, ketoconazole) as well as potent P-gp inhibitors (e.g., cyclosporine). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf#page=2; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204820Orig1s000ClinPharmR.pdf#page=11 Page: 2.0
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf#page=2; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204820Orig1s000ClinPharmR.pdf#page=11 Page: 2.0	yes	yes (co-administration study) Comment: Co-administration with posaconazole (considered a strong CYP3A4 inhibitor) increased AUC of colchcine by approximately 3-fold; Although there are no published case reports for colchicine toxicity when co-administered with the 4 inhibitors that the sponsor employed, i.e., voriconazole, fluconazole, cimetidine and propafenone, several published case reports indicate that colchicine toxicity is observed when it is co-administered with drugs that are potent inhibitors of both P-gp and CYP3A4 (e.g., clarithromycin, ketoconazole) and strong to moderate inhibitors of CYP3A4 (e.g., grapefruit juice, erythromycin). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf#page=2; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204820Orig1s000ClinPharmR.pdf#page=11 Page: 2.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:23359	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:23359
MolPort	MolPort-001-785-612	https://www.molport.com/shop/molecule-link/MolPort-001-785-612
eMolecules	1970918	https://www.emolecules.com/cgi-bin/more?vid=1970918
eMolecules	729203	https://www.emolecules.com/cgi-bin/more?vid=729203

PubMed

Title	Date	PubMed
Acute myelomonocytic leukaemia and multiple myeloma after sulphinpyrazone and colchicine treatment of gout.	1976 Jul 10	1064465
Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.	1991 Jan-Feb	1710653
Acute myopathy induced by colchicine in a cyclosporine treated heart transplant recipient: possible role of the multidrug resistance transporter.	1999 Aug	10455999
Induced differentiation in HT29, a human colon adenocarcinoma cell line.	1999 Aug	10413674
Hypernatraemia and polyuria due to high-dose colchicine in a suicidal patient.	1999 Jun	10383025
Danggui shaoyao san improve colchichine-induced learning acquisition impairment in rats.	2001 Dec	11749816
Abstracts of the Fourth International Symposium on Molecular Insect Science. May 28-June 2, 2002. Tucson, Arizona, USA.	2002	15455051
Improvement of combination chemotherapy tolerance by introduction of polycistronic retroviral vector drug resistance genes MGMT and MDR1 into human umbilical cord blood CD34+ cells.	2002 Mar	11792417
Permanent activation of the human P-glycoprotein by covalent modification of a residue in the drug-binding site.	2003 Jun 6	12711602
The role of the cytoskeleton in mechanotransduction in human osteoblast-like cells.	2003 May	12774890
Differential effects of stretch and compression on membrane currents and [Na+]c in ventricular myocytes.	2003 May-Jul	12732267
[Neurotoxic effects of medications: an update].	2004	15244167
RLIP76 (RALBP1)-mediated transport of leukotriene C4 (LTC4) in cancer cells: implications in drug resistance.	2004 Dec 20	15386349
Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance.	2004 Oct 1	15466210
Acute renal failure associated with an accidental overdose of colchicine.	2005 Oct	16240705
Tetraparesis associated with colchicine is probably due to inhibition by verapamil of the P-glycoprotein efflux pump in the blood-brain barrier.	2005 Sep 17	16148013
Preplaced cell division: a critical mechanism of autoprotection against S-1,2-dichlorovinyl-L-cysteine-induced acute renal failure and death in mice.	2006 Aug	16495211
Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats.	2007	17135773
Zinc and the cytoskeleton in the neuronal modulation of transcription factor NFAT.	2007 Jan	17044076

Patents

Sample Use Guides

In Vivo Use Guide

For prophylaxis of gout flares, the recommended dosage of Colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals.

Route of Administration: Oral

In Vitro Use Guide

Inhibition of the polymerization of brain tubulin was evaluated. Solution of compound in DMSO in serial dilutions was prepared. Reaction mixture contained 0.25 mg of tubulin, 1.0 M monosodium glutamate and approptiate drug concentrations. The reaction mixtures were incubated at 37 °C for 15 min to allow slow binding drugs like colchicine to bind to the tubulin. The reaction mixtures were then chilled on ice, and the polymerization reaction was followed turbidimetrically for 20 min. Polymer formation was confirmed by evaluation of depolymerization at 0°C. Extent of inhibition of polymerization at 20 min in drug-treated samples was always calculated by comparing them to a pair of drug-free samples in each experimental set.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:19:06 GMT 2023` Edited by `admin` on `Fri Dec 15 17:19:06 GMT 2023`
Record UNII	SML2Y3J35T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Colchicine

Official Name

English

NSC-757

Code

English

COLCHICINUM

Common Name

English

ACETAMIDE, N-(5,6,7,9-TETRAHYDRO-1,2,3,10-TETRAMETHOXY-9-OXOBENZO(A)HEPTALEN-7-YL)-,(S)-

Common Name

English

COLCHICINE COMPONENT OF PROBEN-C

Common Name

English

COLCHICINE [WHO-IP]

Common Name

English

(S)-N-(5,6,7,9-TETRAHYDRO-1,2,3,10-TETRAMETHOXY-9-OXOBENZO(A)HEPTALEN-7-YL)ACETAMIDE

Systematic Name

English

COLCHICINE [USP MONOGRAPH]

Common Name

English

COLBENEMID COMPONENT COLCHICINE

Common Name

English

COLCHICINE COMPONENT OF COLBENEMID

Common Name

English

COLCHICINE COMPONENT OF COL-PROBENECID

Common Name

English

Colchicine [WHO-DD]

Common Name

English

COLCHICINE [USP-RS]

Common Name

English

COLCHICINE [EP IMPURITY]

Common Name

English

COLCHCINE [VANDF]

Common Name

English

LODOCO

Brand Name

English

GLOPERBA

Brand Name

English

(-)-COLCHICINE

Common Name

English

MITIGARE COMPONENT COLCHICINE

Brand Name

English

PROBEN-C COMPONENT COLCHICINE

Common Name

English

COLCHICINUM [WHO-IP LATIN]

Common Name

English

COLCRYS

Brand Name

English

COLCHINEOS

Common Name

English

COLCHICINE [ORANGE BOOK]

Common Name

English

COLCHICINE COMPONENT OF MITIGARE

Brand Name

English

COLCHICINE [MI]

Common Name

English

COLCHICINUM [HPUS]

Common Name

English

COLCHICINE [EP MONOGRAPH]

Common Name

English

COLCHICINE [JAN]

Common Name

English

COLCHICINE [MART.]

Common Name

English

COL-PROBENECID COMPONENT COLCHICINE

Common Name

English

COLCHISOL

Common Name

English

COLCHICINE [HSDB]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QM04AC01

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

FDA ORPHAN DRUG

11085

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

FDA ORPHAN DRUG

245707

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

FDA ORPHAN DRUG

245807

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

NCI_THESAURUS

C67421

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

WHO-ATC

M04AC01

Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023

LIVERTOX

NBK548068

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

Code System Code Type Description

ECHA (EC/EINECS)

200-598-5

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

HSDB

3044

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

WHO INTERNATIONAL PHARMACOPEIA

COLCHICINE

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

Description: Pale yellow to pale greenish yellow crystals, amorphous scales or a powder; odourless or almost odourless.Solubility: Soluble in water; freely soluble in ethanol (~750 g/l) TS; slightly soluble in ether R.Category: Antigout drug.Storage: Colchicine should be kept in a tightly closed container, protected from light.Additional information: Colchicine is an alkaloid obtained from Colchicum autumnale L. (Fam. Liliaceae). It darkens on exposureto light. CAUTION: Colchicine is extremely poisonous and must be handled with care.

LACTMED

Colchicine

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

MERCK INDEX

m3725

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

Merck Index

FDA UNII

SML2Y3J35T

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

MESH

D003078

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

ChEMBL

CHEMBL107

Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023

PRIMARY

PUBCHEM

6167

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

NDF-RT

N0000000239

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

P-Glycoprotein Interactions [MoA]

NDF-RT

N0000182141

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

Cytochrome P450 3A4 Inhibitors [MoA]

DAILYMED

SML2Y3J35T

Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023

PRIMARY

CAS

64-86-8

Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023

PRIMARY

NCI_THESAURUS

C385

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

CHEBI

27882

Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023

PRIMARY

EPA CompTox

DTXSID5024845

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

DRUG CENTRAL

726

Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023

PRIMARY

IUPHAR

2367

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

NSC

757

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

RS_ITEM_NUM

1146006

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

RXCUI

2683

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

RxNorm

WIKIPEDIA

COLCHICINE

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

EVMPD

SUB01420MIG

Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023

PRIMARY

SMS_ID

100000090556

Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023

PRIMARY

DRUG BANK

DB01394

Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023

PRIMARY

Related Record Type Details


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE


					74UG0EWZ60

TUBULIN BETA CHAIN

TARGET->INHIBITOR OF AGGREGATION

Comments:

DESTABILIZES TUBULIN POLYMERS

Amount:


					96U5LG549X

MIVOBULIN

DERIVATIVE -> PARENT

Amount:


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE

Qualification:

APICAL

Amount:


					I59XKK41WY

COLCHICINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:

Related Record Type Details


					V9U19L3N0J

2-DEMETHYLCOLCHICINE

METABOLITE LESS ACTIVE -> PARENT

Qualification:

URINE

Amount:


					C939KS8QEL

3-DESMETHYLCOLCHICINE

METABOLITE LESS ACTIVE -> PARENT

Qualification:

URINE

Amount:

Related Record Type Details


					DYD0I854K7

COLCHICOSIDE

IMPURITY -> PARENT

Amount:


					7JX9WZ3SJ5

Colchicine conformational isomer

IMPURITY -> PARENT

Amount:


					U02803H7OJ

GLORIOSINE

IMPURITY -> PARENT

Amount:


					HJ30158L57

COLCHICEINE

IMPURITY -> PARENT

Amount:


					C939KS8QEL

3-DESMETHYLCOLCHICINE

IMPURITY -> PARENT

Amount:

Related Record Type Details


					SML2Y3J35T

Colchicine

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Volume of Distribution	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC

AE	Significance	Dose	Population
Myelosuppression	grade 4, 1 patient	50 mg single, oral Overdose Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/33128536	unknown, 42 years n = 1 Health Status: unknown Age Group: 42 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33128536
Vomiting	13%	1 mg 1 times / week multiple, intravenous Dose: 1 mg, 1 times / week Route: intravenous Route: multiple Dose: 1 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/30604205	unhealthy, 44 years (range: 39.5–48.5 years) n = 15 Health Status: unhealthy Condition: familial Mediterranean fever Age Group: 44 years (range: 39.5–48.5 years) Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/30604205
Diarrhea	20%	1 mg 1 times / week multiple, intravenous Dose: 1 mg, 1 times / week Route: intravenous Route: multiple Dose: 1 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/30604205	unhealthy, 44 years (range: 39.5–48.5 years) n = 15 Health Status: unhealthy Condition: familial Mediterranean fever Age Group: 44 years (range: 39.5–48.5 years) Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/30604205
Injection site reactions	20%	1 mg 1 times / week multiple, intravenous Dose: 1 mg, 1 times / week Route: intravenous Route: multiple Dose: 1 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/30604205	unhealthy, 44 years (range: 39.5–48.5 years) n = 15 Health Status: unhealthy Condition: familial Mediterranean fever Age Group: 44 years (range: 39.5–48.5 years) Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/30604205
Myalgia	27%	1 mg 1 times / week multiple, intravenous Dose: 1 mg, 1 times / week Route: intravenous Route: multiple Dose: 1 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/30604205	unhealthy, 44 years (range: 39.5–48.5 years) n = 15 Health Status: unhealthy Condition: familial Mediterranean fever Age Group: 44 years (range: 39.5–48.5 years) Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/30604205
Nausea	27%	1 mg 1 times / week multiple, intravenous Dose: 1 mg, 1 times / week Route: intravenous Route: multiple Dose: 1 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/30604205	unhealthy, 44 years (range: 39.5–48.5 years) n = 15 Health Status: unhealthy Condition: familial Mediterranean fever Age Group: 44 years (range: 39.5–48.5 years) Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/30604205
Allergic reaction	7%	1 mg 1 times / week multiple, intravenous Dose: 1 mg, 1 times / week Route: intravenous Route: multiple Dose: 1 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/30604205	unhealthy, 44 years (range: 39.5–48.5 years) n = 15 Health Status: unhealthy Condition: familial Mediterranean fever Age Group: 44 years (range: 39.5–48.5 years) Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/30604205
Arthralgia	7%	1 mg 1 times / week multiple, intravenous Dose: 1 mg, 1 times / week Route: intravenous Route: multiple Dose: 1 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/30604205	unhealthy, 44 years (range: 39.5–48.5 years) n = 15 Health Status: unhealthy Condition: familial Mediterranean fever Age Group: 44 years (range: 39.5–48.5 years) Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/30604205
Rhabdomyolysis	grade 5, 1 patient	12 mg single, oral Overdose Dose: 12 mg Route: oral Route: single Dose: 12 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31348292	unknown, 56 years n = 1 Health Status: unknown Age Group: 56 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/31348292
Acute pancreatitis	1 patient Disc. AE	1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17692130	unhealthy, 79 years n = 1 Health Status: unhealthy Age Group: 79 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/17692130
Nausea	1 patient Disc. AE	1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17692130	unhealthy, 79 years n = 1 Health Status: unhealthy Age Group: 79 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/17692130
Vomiting	1 patient Disc. AE	1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17692130	unhealthy, 79 years n = 1 Health Status: unhealthy Age Group: 79 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/17692130
Epigastric pain	severe, 1 patient Disc. AE	1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17692130	unhealthy, 79 years n = 1 Health Status: unhealthy Age Group: 79 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/17692130
Fall	serious, 2 patients	0.6 mg 2 times / day multiple, oral Dose: 0.6 mg, 2 times / day Route: oral Route: multiple Dose: 0.6 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01985425	unhealthy n = 49 Health Status: unhealthy Condition: Thoracic Surgery Population Size: 49 Sources: https://clinicaltrials.gov/ct2/show/NCT01985425
Acute respiratory distress syndrome	serious, 3 patients	0.6 mg 2 times / day multiple, oral Dose: 0.6 mg, 2 times / day Route: oral Route: multiple Dose: 0.6 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01985425	unhealthy n = 49 Health Status: unhealthy Condition: Thoracic Surgery Population Size: 49 Sources: https://clinicaltrials.gov/ct2/show/NCT01985425

Details

SMILES

InChI

DescriptionSources: https://www.drugs.com/pro/colchicine.html

CNS Activity

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.drugs.com/pro/colchicine.html

C_max

T_1/2

F_unbound